Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Capital Expenditures (2023 - 2025)

Nuvation Bio (NUVB) has disclosed Capital Expenditures for 3 consecutive years, with $7.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 4520.0% to $7.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.0 million, a N/A change, with the full-year FY2025 number at $8.0 million, changed N/A from a year prior.
  • Capital Expenditures was $7.7 million for Q4 2025 at Nuvation Bio, up from $12000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $7.7 million in Q4 2025 to a low of -$175000.0 in Q4 2024.
  • A 3-year average of $733545.5 and a median of $22000.0 in 2023 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: crashed 1446.15% in 2024, then soared 4520.0% in 2025.
  • Nuvation Bio's Capital Expenditures stood at $13000.0 in 2023, then plummeted by 1446.15% to -$175000.0 in 2024, then skyrocketed by 4520.0% to $7.7 million in 2025.
  • Per Business Quant, the three most recent readings for NUVB's Capital Expenditures are $7.7 million (Q4 2025), $12000.0 (Q3 2025), and $181000.0 (Q2 2025).